Purple Biotech (PPBT) Capital Expenditures (2017 - 2023)
Purple Biotech (PPBT) posted quarterly Capital Expenditures of $6000.0 for Q4 2023, down 88.46% year-over-year from $52000.0 in Q4 2022, and up 500.0% quarter-over-quarter from $1000.0 in Q3 2023.
Purple Biotech (PPBT) Capital Expenditures (2017 - 2023) Analysis & Trends
Purple Biotech (PPBT) has reported Capital Expenditures for 7 consecutive years, with $6000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Capital Expenditures fell 88.46% year-over-year to $6000.0; the TTM figure through Dec 2023 stood at $3000.0 (down 88.46% YoY), while the FY2025 annual figure was $3000.0, changed N/A from the prior year.
- Capital Expenditures grew to $6000.0 in Q4 2023 per PPBT's latest filing, from $1000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $52000.0 in Q4 2022 and bottomed at -$156000.0 in Q4 2020.
- Historically, Capital Expenditures has averaged -$17928.6 across 5 years, with a median of -$6000.0 in 2021.
- Annual changes were most pronounced in 2020 — Capital Expenditures tumbled 5100.0% — and 2022, when it surged 966.67%.
- Purple Biotech's Capital Expenditures stood at -$3000.0 in 2019, then sank by 5100.0% to -$156000.0 in 2020, then surged by 96.15% to -$6000.0 in 2021, then soared by 966.67% to $52000.0 in 2022, then sank by 88.46% to $6000.0 in 2023.
- Business Quant data shows PPBT's Capital Expenditures at $6000.0 in Q4 2023, $1000.0 in Q3 2023, and -$1000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Purple Biotech | 133.62 | 133.62 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 6,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Mar 31, 2023 | -3,000.00 |
| Mar 31, 2023 | -3,000.00 |
| Dec 31, 2022 | 52,000.00 |
| Dec 31, 2022 | 52,000.00 |
| Sep 30, 2022 | -6,000.00 |
| Sep 30, 2022 | -6,000.00 |
| Jun 30, 2022 | -6,000.00 |
| Jun 30, 2022 | -6,000.00 |
| Mar 31, 2022 | -14,000.00 |
| Mar 31, 2022 | -14,000.00 |
| Dec 31, 2021 | -6,000.00 |
| Dec 31, 2021 | -6,000.00 |
| Sep 30, 2021 | -6,000.00 |
| Sep 30, 2021 | -6,000.00 |